Key facts
- CytoVale’s last known valuation is $340.0M.
- It has raised $228.2M across 3 recorded rounds; the latest was Early Stage VC ($7.4M) in Oct 2019.
- Notable investors include Alumni Ventures, US National Science Foundation, Google for Startups, National Institutes of Health, Western Technology Investment — 35 tracked in total.
- CytoVale has filed 4 Form Ds with the SEC since 2017, most recently Jan 2022 ($16.4M sold to 23 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 3 rounds
- ·The complete investor list — 35 names
- ·Watchlist + deal alerts for CytoVale
Funding rounds
3 roundsAbout CytoVale
Developer of biophysical markers designed to revolutionize diagnostics using cell mechanics and machine learning. The company's biomarkers are based on the mechanical properties of individual cells by using microfluidics to route and probe cells which can measure multiple biomarkers at one time, enabling physicians to detect early symptoms of sepsis, improve patient outcomes and reduce treatment costs.
- Sector
- Healthcare
- HQ
- South San Francisco, CA, United States
- Founded
- 2013
- Employees
- 124
- Website
- cytovale.com/
- Ownership
- Privately Held (backing)
CytoVale doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in CytoVale shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on CytoVale in its N-PORT filings yet. We sweep new filings monthly.